Stocks discussed in the in-depth session of Jim Cramer’s Mad Money TV program, Tuesday October 16. Click on a stock ticker for more analysis:
Seeking Alpha publishes a summary of Jim Cramer's stock picks every day including: Mad Money Recap, Lightning Round, Stop Trading and his Wall Street Confidential Picks.
Getting it Straight: Align Technology (ALGN)
Since vanity stocks have had a good track record on Mad Money, Cramer discussed ALGN and its product Invisalign, which uses plastic aligners to straighten teeth in 9 to 18 months. Cramer calls Invisalign the "best of the best" and expects ALGN to blow away its numbers for the third consecutive quarter when it reports in the next few weeks. While the stock is not cheap, it has been consistently underestimated; "The shorts will not need braces, but implants or dentures because they're going to get kicked in the teeth with this one," Cramer said. While estimates for growth are at 34%, Cramer thinks these numbers are too conservative and add ALGN is a good stock to own during a slowdown.
Related: H.S. Ayoub reported on ALGN's previous earnings victory.
Auto Suggestion: LKQ (LKQX)
Cramer expects analysts to raise estimates for LKQ since this supplier of recycled auto parts has recently acquired Keystone Automotive Industries, and should see a significant earnings increase. He also noted LKQ's secondary offering brought the stock up, and compares the company to Crocs, which started out as a much sought-after stock. LKQ may get business from insurance companies looking for inexpensive auto repairs and has a risk of 4 down and a reward of 15 points up. He predicts the stock could reach $50 and would not pay much more than its current price, $34.60.
Related: Zachary Scheidt discusses LKQ's acquisitions and business with insurance companies.
Hear Ye, Hear Ye: Sonic Innovations (SNCI)
Cramer says hearing loss may be the new market trend, and recommended SNCI which produces hearing aids which are small and have great sound quality. The stock should rise on Medicare legislation allowing patients to go to ordiologists without referrals. Even without the legislation, Cramer predicts SNCI could go to $13. While there is substantial competition and the devices are not covered by insurance, Cramer is bullish, but he recommended caution, buying with limit orders and passing on the stock if it can't be bought at around its current price of $9.76.
CEO Interview: Joel Kiani, Masimo (MASI)
Masimo's pulse oximeter, which measures the amount of oxygen in the body, has been shown to be the best, and Joel Kiani discussed the $2 to $3 billion market potential for the company's products. Cramer added Masimo won't be adversely affected by an economic slowdown and it is a stock "for anyone who needs a medical healthcare company that is small cap."
Get Cramer's Picks by e-mail -- it's free and takes only a few seconds to sign up.
Seeking Alpha is not affiliated with Jim Cramer, CNBC or TheStreet.com